AMCP Comment Letter on Medicare Drug Price Negotiation Program Draft Guidance
AMCP recognizes the importance of efforts to make prescription drugs more affordable for Medicare beneficiaries and urges CMS to continually and rigorously oversee the program’s implementation and its broader effects to ensure that it does not unintentionally hinder innovation and the development of new therapies. CMS should monitor the downstream impact of the Medicare Drug Price Negotiation Program on innovation and drug development and take appropriate action as needed to ensure that the United States remains the leader in pharmaceutical innovation.
Related
In February 2026, Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) introduced the Break Up Big Medicine Act (S. 3822). The bipartisan legislation, referred to the Senate Judiciary Committee, aims to prohibit pharmacy benefit managers (PBMs), health insurers, and prescription drug or medical device wholesalers from being under common ownership with certain medical service providers or provider groups, including in-patient or outpatient pharmacies.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
